Sreekhar Cheboyina
About Sreekhar Cheboyina
Sreekhar Cheboyina is a Senior Director of Drug Products Development and Manufacturing at BridgeBio, with extensive experience in pharmaceutical formulation and manufacturing. He has held various leadership roles across multiple companies, including Mallinckrodt, Aimmune Therapeutics, and Teva Pharmaceuticals, and holds a Ph.D. in Pharmaceutics from the University of Mississippi.
Current Role at BridgeBio
Sreekhar Cheboyina serves as the Senior Director of Drug Products Development and Manufacturing at BridgeBio. He has held this position since 2022 and is based in the San Francisco Bay Area. In this role, he oversees the development and manufacturing processes of drug products, contributing to the company's mission of advancing innovative therapies.
Previous Experience in Pharmaceutical Development
Before joining BridgeBio, Sreekhar held various significant positions in the pharmaceutical industry. He worked at Aimmune Therapeutics as Associate Director of Product Development from 2019 to 2020. Prior to that, he was a Principal Pharma Tech Specialist at Allergan from 2012 to 2016, and he also served as a Group Leader/Principal Formulations Scientist at Mallinckrodt from 2011 to 2012.
Educational Background and Qualifications
Sreekhar Cheboyina holds a Ph.D. in Pharmaceutics from the University of Mississippi, where he studied from 2001 to 2006. He also earned a Master's degree in Pharmacy and a Bachelor's degree in Pharmacy from the Birla Institute of Technology and Science, Pilani. Additionally, he holds a Chemical Design for Six Sigma certification.
Expertise in Drug Formulation and Manufacturing
Sreekhar has extensive expertise in the formulation development of oral immediate release and complex controlled release solid dosage forms. He has experience with fluid bed processing, Wurster coatings, granulation, and drying. His background includes handling potent compounds and conducting complex manufacturing investigations and technical assessments.
Regulatory Expertise and Product Development
Sreekhar Cheboyina serves as a Subject Matter Expert for regulatory audits, including those conducted by the FDA and MHRA. He has a proven track record in developing 505(b)(2) and generic products for Paragraph IV filings, as well as in developing platform technologies and early formulation development.